 | Up a level |
Trojani, V; Grehn, M; Botti, A; Balgobind, B; Savini, A; Boda-Heggemann, J; Miszczyk, M; Elicin, O; Krug, D; Andratschke, N; Schmidhalter, D; van Elmpt, W; Bogowicz, M; de Areba, J; Dolla, L; Ehrbar, S; Fernandez-Velilla, E; Fleckenstein, J; Cabañero, D Granero; Henzen, D; ... (2024). Refining Treatment Planning in STereotactic Arrhythmia Radioablation (STAR): Benchmark Results and Consensus Statement from the STOPSTORM.eu Consortium. (In Press). International journal of radiation oncology, biology, physics Elsevier 10.1016/j.ijrobp.2024.07.2331
Siklody, C Herrera; Schiappacasse, L; Jumeau, R; Reichlin, T; Saguner, A M; Andratschke, N; Elicin, O; Schreiner, F; Kovacs, B; Mayinger, M; Huber, A; Verhoeff, J J C; Pascale, P; Solana Muñoz, J; Luca, A; Domenichini, G; Moeckli, R; Bourhis, J; Ozsahin, E M and Pruvot, E (2023). Recurrences of ventricular tachycardia after stereotactic arrhythmia radioablation arise outside the treated volume: analysis of the swiss cohort. Europace, 25(10) Oxford University Press 10.1093/europace/euad268
Moustakis, C; Blanck, O; Chan, Mkh; Boda-Heggemann, J; Andratschke, N; Duma, M-N; Albers, D; Bäumer, C; Fehr, R; Körber, S A; Schmidhalter, D; Alraun, M; Baus, W W; Beckers, E; Dierl, M; Droege, S; Ebrahimi Tazehmahalleh, F; Fleckenstein, J; Guckenberger, M; Heinz, C; ... (2022). Planning benchmark study for SBRT of liver metastases: Results of the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery. International journal of radiation oncology, biology, physics, 113(1), pp. 214-227. Elsevier 10.1016/j.ijrobp.2022.01.008
Stelmes, J-J; Vu, E; Grégoire, V; Simon, C; Clementel, E; Kazmierska, J; Grant, W; Ozsahin, M; Tomsej, M; Vieillevigne, L; Fortpied, C; Hurkmans, E C; Branquinho, A; Andratschke, N; Zimmermann, F; Weber, D-C (2021). Quality assurance of radiotherapy in the ongoing EORTC 1420 "Best of" trial for early stage oropharyngeal, supraglottic and hypopharyngeal carcinoma: results of the benchmark case procedure. Radiation oncology, 16(1), p. 81. BioMed Central 10.1186/s13014-021-01809-2
Peters, S; Felip, E; Dafni, U; Belka, C; Guckenberger, M; Irigoyen, A; Nadal, E; Becker, Antje; Vees, H; Pless, M; Martinez-Marti, A; Tufman, A; Lambrecht, M; Andratschke, N; Piguet, A C; Kassapian, M; Roschitzki-Voser, H; Rabaglio, Manuela; Stahel, R A; Vansteenkiste, J; ... (2019). Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial. Lung cancer, 133, pp. 83-87. Elsevier 10.1016/j.lungcan.2019.05.001
Klement, Rainer J; Abbasi-Senger, N; Adebahr, S; Alheid, H; Allgaeuer, M; Becker, G; Blanck, O; Boda-Heggemann, J; Brunner, T; Duma, M; Eble, M J; Ernst, I; Gerum, S; Habermehl, D; Hass, P; Henkenberens, C; Hildebrandt, G; Imhoff, D; Kahl, H; Klass, Natalie Désirée; ... (2019). The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC cancer, 19(1), p. 173. BioMed Central 10.1186/s12885-019-5362-5
Klement, R J; Hoerner-Rieber, J; Adebahr, S; Andratschke, N; Blanck, O; Boda-Heggemann, J; Duma, M; Eble, M J; Eich, H C; Flentje, M; Gerum, S; Hass, P; Henkenberens, C; Hildebrandt, G; Imhoff, D; Kahl, K H; Klass, Natalie Désirée; Krempien, R; Lohaus, F; Petersen, C; ... (2018). Stereotactic body radiotherapy (SBRT) for multiple pulmonary oligometastases: Analysis of number and timing of repeat SBRT as impact factors on treatment safety and efficacy. Radiotherapy and oncology, 127(2), pp. 246-252. Elsevier 10.1016/j.radonc.2018.02.016
Tanadini-Lang, S; Rieber, J; Filippi, A R; Fode, M M; Streblow, J; Adebahr, S; Andratschke, N; Blanck, O; Boda-Heggemann, J; Duma, M; Eble, M J; Ernst, I; Flentje, M; Gerum, S; Hass, P; Henkenberens, C; Hildebrandt, G; Imhoff, D; Kahl, H; Klass, Natalie Désirée; ... (2017). Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiotherapy and oncology, 123(2), pp. 182-188. Elsevier 10.1016/j.radonc.2017.01.003
